| Characteristic | Orphan drug revenue in billion U.S. dollars |
|---|---|
| Revlimid (Celgene/BelGene) | 9.82 |
| Rituxan (Roche) | 6.93 |
| Imbruvica (AbbVie/J&J) | 4.45 |
| Keytruda (Merck & Co/Otsuka) | 3.8 |
| Soliris (Alexion) | 3.56 |
| Jakafi (Incyte/Novartis) | 2.36 |
| Pomalyst (Celgene) | 2.04 |
| Darzalex (J&J) | 2.03 |
| Yervoy (Ono(BMS) | 1.33 |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Loading statistic...
Download
Source
Release date
April 2019
Region
Worldwide
Survey time period
2018
Supplementary notes
* Products that have orphan and non-orphan drug designations and are expected to generate less than 50% of their sales in 2018 and 2024 from their orphan-designated indication/s, are excluded from this statistic. This has led to the exclusion of therapies such as Avastin, Opdivo, Enbrel, Herceptin, Humira and Remicade.
Citation formats









